Associations Between Aggregate NLP-Extracted Conflicts of Interest and Adverse Events by Drug Product

• DOI: 10.3233/shti220106
• Publication Date: 2022-06-07T09:31:58Z
• Authors: S. Scott Graham; Zoltan P. Majdik; Johua B. Barbour; Justin F. Rousseau
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Conflict of Interest; Disclosure; 3. Good health

This study evaluates associations between aggregate conflicts of interest (COI) and drug safety. We used a machine-learning system to extract and classify COI from PubMed-indexed disclosure statements. Individual conflicts were classified as Type 1 (personal fees, travel, board memberships, and non-financial support), Type 2 (grants and research support), or Type 3 (stock ownership and industry employment). COI were aggregated by type compared to adverse events by product. Type 1 COI are associated with a 1.1-1.8% increase in the number of adverse events, serious events, hospitalizations, and deaths. Type 2 COI are associated with a 1.7-2% decrease in adverse events across severity levels. Type 3 COI are associated with an approximately 1% increase in adverse events, serious events, and hospitalizations, but have no significant association with adverse events resulting in death. The findings suggest that COI policies might be adapted to account the relative risks of different types of financial relationships.